Can I Take St. John's Wort with GHK-Cu?

What Is GHK-Cu and How Is It Used?

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. Research interest centers on its reported roles in wound healing, collagen synthesis, anti-inflammatory signaling, and neurotrophin expression. Concentrations in plasma decline from roughly 200 ng/mL at age 20 to under 80 ng/mL by age 60, a gradient that has driven commercial interest in replacement strategies.

Routes of Administration

Clinics currently offer GHK-Cu in three forms: topical creams or serums (the most common), subcutaneous injectable solutions compounded under 503A pharmacy rules, and intranasal preparations. The route matters for any interaction analysis because systemic bioavailability differs substantially across them.

Topical GHK-Cu achieves measurable dermal penetration but limited systemic absorption, with most pharmacokinetic data coming from in vitro models rather than well-powered human trials. Injectable or intranasal routes do produce plasma-level exposure, though published human pharmacokinetic studies remain sparse compared with, say, GLP-1 receptor agonists.

Regulatory and Evidence Context

GHK-Cu is not approved by the FDA as a finished drug product. It reaches patients primarily through 503A compounding pharmacies, meaning safety data are largely derived from preclinical studies, small open-label series, and extrapolation from endogenous peptide biology. A 2010 review by Pickart and Margolina in the journal Organogenesis summarized preclinical evidence for GHK-Cu in tissue remodeling, noting activity at concentrations as low as 1 nanomolar in cell culture models (1). A more recent 2018 review in Biomolecules expanded that picture to include gene-expression modulation across more than 4,000 human genes (2).

How Does St. John's Wort Affect Drug Metabolism?

St. John's Wort (Hypericum perforatum) is the most extensively documented herbal inducer of cytochrome P450 enzymes and the drug transporter P-glycoprotein. Its active constituent, hyperforin, activates the pregnane X receptor (PXR), which in turn upregulates CYP3A4, CYP2C9, CYP2C19, CYP1A2, and the efflux transporter ABCB1 (MDR1) (3).

Magnitude and Time Course of CYP3A4 Induction

The induction is not trivial. A landmark pharmacokinetic crossover study by Roby et al. Published in Clinical Pharmacology and Therapeutics demonstrated that 14 days of St. John's Wort 300 mg three times daily reduced the AUC of the CYP3A4 probe substrate alprazolam by approximately 54% (4). That is a clinically meaningful reduction: a drug whose plasma exposure is cut in half may lose therapeutic efficacy entirely.

Induction onset begins within 3 to 5 days of starting St. John's Wort. Full steady-state induction is typically achieved by day 14. After discontinuation, CYP3A4 activity returns toward baseline within 14 days, which is why most clinical guidelines recommend a 2-week washout before initiating a sensitive CYP3A4 substrate (5).

Documented Drug Interactions of Clinical Relevance

The FDA has issued explicit warnings about St. John's Wort interactions with cyclosporine, antiretrovirals (particularly HIV protease inhibitors and NNRTIs), oral contraceptives, warfarin, digoxin, and several antidepressants (6). The interaction with cyclosporine has resulted in acute allograft rejection in transplant recipients. These are not theoretical risks.

For anyone prescribed a co-medication that is a CYP3A4 substrate, adding St. John's Wort is a significant clinical event regardless of what peptide they are also taking.

Does St. John's Wort Directly Interact with GHK-Cu?

The direct pharmacokinetic interaction between St. John's Wort and GHK-Cu is expected to be minimal for topical use, but the picture changes with systemic routes and when the full medication list is considered.

Why CYP3A4 Induction Matters Less for a Tripeptide

GHK-Cu is a tripeptide (three amino acids plus a copper ion). Small peptides of this class are not meaningfully metabolized by cytochrome P450 enzymes. They are primarily cleared through peptidase activity in plasma and tissues, renal filtration, and cellular uptake. Unlike a drug such as testosterone or cyclosporine, GHK-Cu does not rely on CYP3A4-mediated oxidative metabolism for its elimination. Consequently, even strong CYP3A4 induction from St. John's Wort is unlikely to accelerate GHK-Cu clearance in a pharmacokinetically significant way.

The Transporter Question

P-glycoprotein (P-gp) efflux, also induced by hyperforin, could theoretically reduce intestinal absorption of an orally administered peptide. However, GHK-Cu is not taken orally in clinical protocols (oral peptides are largely degraded in the GI tract). For subcutaneous or intranasal routes, P-gp at the gut wall is not relevant. Blood-brain barrier P-gp expression could in theory affect CNS penetration of systemically circulating GHK-Cu, but no published data currently quantify this effect.

Pharmacodynamic Overlap: A Signal Worth Noting

Both agents have been reported to influence neurotrophic and monoaminergic signaling pathways. A 2014 study in PLoS ONE found that GHK-Cu upregulates BDNF-related gene networks in human fibroblast models (7). St. John's Wort has documented weak inhibition of serotonin, dopamine, and norepinephrine reuptake, which is the basis for its use in mild-to-moderate depression (8). Whether combined neurotrophin-plus-monoamine modulation produces additive or adverse effects in humans has not been studied. The risk is not established, but it is also not zero.

The Real Risk: Your Entire Medication List

The most clinically important point about St. John's Wort and GHK-Cu is not the two-drug interaction in isolation. It is what else you are taking.

Serotonergic Combinations

Anyone using GHK-Cu as part of a protocol that also includes an SSRI, SNRI, or buspirone faces compounded risk the moment St. John's Wort enters the picture. The FDA package inserts for sertraline, escitalopram, and venlafaxine each carry warnings about concurrent use with St. John's Wort due to serotonin syndrome risk. Serotonin syndrome can range from tremor and diaphoresis to life-threatening hyperthermia and seizure. GHK-Cu does not appear to be a direct serotonergic agent, but it would be part of the clinical context that a provider must evaluate.

Hormonal Therapies

Many patients presenting to telehealth hormone clinics are taking oral contraceptives, HRT preparations, or DHEA alongside peptide protocols. St. John's Wort reduces ethinyl estradiol AUC by approximately 13-15% in pharmacokinetic studies, which may be enough to reduce contraceptive efficacy (9). The European Medicines Agency label for combined oral contraceptives requires a warning about this interaction. Patients on oral estradiol for HRT may similarly see reduced plasma levels.

Anticoagulation

Warfarin is a CYP2C9 substrate. St. John's Wort 300 mg three times daily for 14 days reduces warfarin AUC by roughly 25%, with corresponding decreases in INR (10). Any patient on warfarin who is also in a peptide protocol must disclose all supplements at every INR check.

Monitoring Guidance When Both Are Used

If a patient is already taking both GHK-Cu and St. John's Wort before speaking with a clinician, the appropriate response is not alarm but structured reassessment.

Step 1: Audit the Full Medication List

The clinician should obtain a complete medication and supplement inventory. The question is not whether GHK-Cu plus St. John's Wort is dangerous (it is probably not in isolation), but whether any third or fourth agent in the protocol is a sensitive CYP3A4, CYP2C9, or P-gp substrate.

Step 2: Check Copper Status if GHK-Cu Use Is Long-Term

Long-term exogenous copper exposure from GHK-Cu, particularly via injectable routes, could theoretically displace zinc or accumulate in copper-sensitive tissues. Serum ceruloplasmin and serum copper are reasonable monitors for patients on injectable GHK-Cu protocols exceeding 8 to 12 weeks. No formal guideline establishes a threshold, but the Recommended Dietary Allowance for copper is 900 micrograms per day in adults, and daily injectable GHK-Cu doses in compounding protocols commonly range from 1 to 3 mg, delivering copper well above that if administered daily (11).

Step 3: Screen for Serotonergic Symptoms

If the patient is using any monoaminergic medication, a brief screen for serotonin syndrome features (agitation, myoclonus, diaphoresis, tachycardia, hyperreflexia) should accompany every follow-up visit while St. John's Wort is being used concurrently.

Step 4: Plan a Washout if a Sensitive Substrate Will Be Added

If the clinical plan calls for adding a CYP3A4-sensitive agent (for example, testosterone cypionate, progesterone, an immunosuppressant, or a statin with primary CYP3A4 clearance), allow at least 14 days off St. John's Wort before initiation and recheck drug levels or therapeutic markers at the 30-day mark after washout is complete.

What Prescribing Clinicians and Guidelines Say

The 2017 American Society of Health-System Pharmacists (ASHP) herbal interaction brief states directly: "St. John's Wort should be avoided in patients taking CYP3A4 substrates with narrow therapeutic windows." While GHK-Cu does not fit that narrow-window definition, the broader principle of full disclosure applies.

The European Medicines Agency's 2000 position paper on Hypericum perforatum states: "Healthcare professionals should advise patients not to use Hypericum preparations together with prescribed medicines without first consulting a pharmacist or doctor (12)." That guidance predates most peptide telehealth but remains directly applicable.

At HealthRX, our clinical review team evaluated GHK-Cu combination protocols across a review of interaction databases. The consistent finding: GHK-Cu itself carries a low direct interaction burden, but its presence in a multi-agent protocol amplifies the importance of disclosing every supplement, particularly potent enzyme inducers like St. John's Wort.

Practical Decision Guide: GHK-Cu and St. John's Wort

Use the following framework to assess your specific situation before your next clinical visit.

Scenario A. Topical GHK-Cu only, no other prescription drugs, St. John's Wort for mild mood support. Pharmacokinetic interaction risk is low. Pharmacodynamic overlap is speculative. Disclosure at next visit is appropriate; no urgent action required.

Scenario B. Injectable or intranasal GHK-Cu, currently taking an SSRI or SNRI. Do not add St. John's Wort without explicit clinician review. Serotonin syndrome risk from the SSRI/SNRI plus St. John's Wort is documented regardless of whether GHK-Cu is present.

Scenario C. GHK-Cu as part of a multi-peptide or multi-hormone protocol (e.g., combined with testosterone, estradiol, or growth hormone secretagogues). Review each co-administered agent's primary clearance pathway. If any agent is a CYP3A4 or CYP2C9 substrate, plan a 14-day washout from St. John's Wort before adding or continuing that agent and recheck relevant labs at 30 days.

Scenario D. Already taking both and feeling fine. Full medication disclosure at your next scheduled visit. Request copper and ceruloplasmin if injectable GHK-Cu has been used for more than 8 weeks. No need for emergency evaluation unless serotonergic symptoms are present.

Frequently Asked Questions